Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 15/20 | 0.50 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.30 |
| ▸ | PRKX | P51817 | 1/20 | 0.30 |
| ▸ | IKBKE | Q14164 | 1/20 | 0.30 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.30 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16637224 | 0.94 | FFAR1 (0.54) | FFAR1CYP2C8CYP2C9 | |
| SCHEMBL17925138 | 0.94 | FFAR1 (0.54) | FFAR1CYP2C8CYP2C9 | |
| SCHEMBL16647619 | 0.92 | FFAR1 (0.49) | FFAR1CYP2C8CYP2C9 | |
| SCHEMBL17925140 | 0.92 | FFAR1 (0.54) | FFAR1CYP2C8CYP2C9S1PR1FFAR4 | |
| SCHEMBL16637065 | 0.92 | FFAR1 (0.54) | FFAR1CYP2C8CYP2C9S1PR1FFAR4 | |
| SCHEMBL17930524 | 0.91 | FFAR1 (0.55) | FFAR1CYP2C8CYP2C9 | |
| SCHEMBL16647617 | 0.91 | FFAR1 (0.53) | FFAR1CYP2C8CYP2C9 | |
| SCHEMBL15471396 | 0.89 | FFAR1 (0.58) | FFAR1CYP2C8CYP2C9FFAR4 | |
| SCHEMBL16647648 | 0.89 | FFAR1 (0.55) | FFAR1CYP2C8CYP2C9FFAR4 | |
| SCHEMBL16647620 | 0.89 | FFAR1 (0.55) | FFAR1CYP2C8CYP2C9FFAR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3055288-B1 | ANTIDIABETIC TRICYCLIC COMPOUNDS | MERCK SHARP & DOHME (US) | 2020-12-16 | — | — | EP | claimed |
| EP-3055288-B1 | ANTIDIABETIC TRICYCLIC COMPOUNDS | MERCK SHARP & DOHME (US) | 2020-12-16 | — | — | EP | disclosed |
| EP-3055288-B1 | ANTIDIABETIC TRICYCLIC COMPOUNDS | MERCK SHARP & DOHME (US) | 2020-12-16 | — | — | EP | disclosed |
| US-9932311-B2 | Antidiabetic tricyclic compounds | MERCK SHARP & DOHME CORP. (US) | 2018-04-03 | — | — | US | disclosed |
| US-20160207887-A1 | ANTIDIABETIC TRICYCLIC COMPOUNDS | MERCK SHARP & DOHME LLC | 2016-07-21 | — | — | US | disclosed |
| WO-2015051725-A1 | ANTIDIABETIC TRICYCLIC COMPOUNDS | MERCK SHARP & DOHME CORP. (US) | 2015-04-16 | — | — | WO | disclosed |
| WO-2015051496-A1 | ANTIDIABETIC TRICYCLIC COMPOUNDS | MERCK SHARP & DOHME CORP. (US) | 2015-04-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160207887-A1 | ANTIDIABETIC TRICYCLIC COMPOUNDS | GPR119, GPR65, GPR55 | FFAR1 23/4885CYP2C8 1149/4885CYP2C9 2352/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.